Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Diseases and Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ZAP70 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZAP70 Recombinant Active Kinase / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ZAP70 Products |
| Gene Delivery | ZAP70 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and T-cell reconstitution. |
View ZAP70 Products |
| Benchmark Ab | Anti-ZAP70 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Flow Cytometry. |
View ZAP70 Products |
| Validator | ZAP70 siRNA Set For knockdown verification in primary T cells and Jurkat lines. |
View ZAP70 Products |
| Related Target A | SYK Syk family kinase. Crucial counter-screening target to ensure ZAP70 inhibitor selectivity and avoid off-target toxicity. |
View SYK Products |
| Related Target B | LCK Src-family kinase upstream of ZAP70. Essential for examining the TCR signaling cascade. |
View LCK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Syk Homology Off-Target Screening | Highly purified ZAP70 and SYK kinase domain proteins available with >95% purity verified by SDS-PAGE |
| Phosphorylation-State Specificity | Recombinant proteins designed with specific phosphorylation site mutations (e.g., Y319) for mechanism mapping |
| Lack of Controls | Sequence-verified clinical benchmark and tool antibodies included |
| False Positives | Validated siRNA pool included for target knockdown specificity checks |
Live ZAP70 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZAP70 therapeutics is intensifying, with major players shifting focus from non-selective kinase inhibitors to highly selective small molecule inhibitors and PROTAC degraders. As first-generation autoimmune therapies reach the clinic, the next wave of R&D is targeting ZAP70-positive Chronic Lymphocytic Leukemia (CLL) and refractory T-cell mediated autoimmune diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Bristol Myers Squibb, Pfizer | Rheumatoid Arthritis, IBD | Selectivity Assay (Need Mutant vs WT Active Kinase Proteins) |
| PROTAC (Degrader) | Academic Institutions, Biotech Startups | CLL, T-Cell Lymphoma | Protein Degradation Assay (Need high-purity full-length ZAP70) |
| siRNA / Therapeutics | Alnylam, Tool Devs | Inflammatory Disorders | Knockdown Validation (Need Lentivirus/siRNA controls) |